Strides Pharma Science Limited has received formal approval from the NCLT, Bengaluru Bench, for the scheme of arrangement involving its subsidiary, Arco Lab Private Limited. The demerger segregates Arco Lab’s Life Sciences and Digital Innovation businesses into Pivot Path Private Limited. This strategic move aims to streamline operations, with the appointed date for the transfer set for April 10, 2025. Following the order, Pivot Path will become a wholly owned subsidiary of Strides.
Approval of Strategic Demerger
On May 18, 2026, the National Company Law Tribunal (NCLT) approved the scheme of arrangement for the demerger of the ‘Demerged Undertaking’ from Arco Lab Private Limited. The order, which was officially made available on the NCLT portal on May 20, 2026, marks a significant milestone in the organizational restructuring of Strides Pharma Science Limited.
Restructuring and Business Focus
The demerger process involves the transition of Arco Lab’s Life Sciences business and Digital Innovation business into Pivot Path Private Limited. This move is designed to create a more focused business structure. Effective as of the appointed date of April 10, 2025, the assets and operations of the identified undertakings will vest with Pivot Path.
Post-Demerger Organizational Structure
Upon the scheme becoming fully effective, Pivot Path will transition into a wholly owned subsidiary of Strides. The Boards of Directors for both Arco Lab and Pivot Path will finalize the record date for the formal allotment of equity shares. As part of this transition, existing shares of Pivot Path held by Arco Lab will be extinguished, and new equity will be issued to Strides Pharma Science Limited based on the defined share entitlement ratio.
Source: BSE
